T-DM1 reduces long-term risk of death in HER2-positive breast cancer patients
In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...
Medscape3 小时
Trastuzumab Emtansine Ups Long-term Survival in HER2-Positive Breast Cancer
Patients with HER-2 positive early breast cancer with residual invasive disease after neoadjuvant therapy were randomly ...
Muscular Dystrophy News3 小时
DYNE-101 is leading to functional gains for DM1 patients in trial
DYNE-101 eased myotonia and led to other functional improvements for people with myotonic dystrophy type 1 (DM1) in a ...